✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company. According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the market predicts, possibly as early as the fourth quarter of 2025.

According to BMO Capital’s analysis, even with a low alpha spend, this intermediate review may show statistical significance. The firm notes that a favorable readout might enhance public perception of beta-amyloid Alzheimer’s treatment and possibly increase its long-term market potential to include patients whose disease has not yet progressed.

In the best-case scenario, BMO Capital predicts that Eli Lilly’s stock might rise by about 7% due to positive interim results.

Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds